To include your compound in the COVID-19 Resource Center, submit it here.

Telik up on Phase II data

TELK was up $1.14 to $15.75 on 2.4 million shares on Monday after reporting interim Phase II data for its Telcyta

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE